MANKIND PHARMA REPORTED 16.2% YOY DROP IN NET PROFIT AT ₹380.2 CRORE FOR Q3CFY. REVENUE FROM OPERATIONS INCREASED 24% YOY TO ₹3,230 CRORE. EBITDA SURGED 36.8% YOY TO ₹830 CRORE. 
#StockMarketNews
#StockMarketNews